Dendritic cell targeting with C-type lectins for improvement of allergen immunotherapy - 04/08/16

Key words : Dendritic cells, targeting, mannan, C-type lectins, allergen immunotherapy
Le texte complet de cet article est disponible en PDF.
| Disclosure of potential conflict of interest: S. Vieths reports grants from Monsanto Company; personal fees from the American Academy of Allergy, Asthma & Immunology, Deutsche Dermatologische Gesellschaft, Ärzteverband Deutscher Allergologen, Swiss Society for Allergy and Immunology, Schattauer, Elsevier, and Karger; non-financial support from German Research Foundation, Federal Institute for Risk Assessment, European Directorate for the Quality of Medicines and Health Care, European Academy of Allergy and Clinical Immunology, Deutscher Allergie- und Asthmabund, German Chemical Society (GDCh), AKM Allergiekongress, and International Union of Immunological Societies; and personal fees from University Hospital Gießen/Marburg, and University of Bonn, outside the submitted work. S. Schülke declares that he has no relevant conflicts of interest. |
Vol 138 - N° 2
P. 568-570 - août 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
